Skip to main content

Table 1 Demographic and clinical data

From: Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients

Variables N (%) Variables N (%)
Gender Major surgery
 Female 40 (57.1) No 60 (85.7)
 Male 30 (42.9) Yes 10 (14.3)
Habits Minor surgery
 Smokers 18 (25.7) No 40 (57.1)
 Non-smokers 52 (74.3) Yes 30 (42.9)
History of bilharziasis Hazardous injection
 No 37 (52.9) No 56 (80)
 Yes 33 (47.1) Yes 14 (20)
Oral treatment (bilharziasis) Diabetes
 No 44 (62.9) No 50 (71.4)
 Yes 26 (37.1) Yes 20 (28.6)
Parenteral treatment (bilharziasis) HTN
 No 61 (87.1) No 48 (68.6)
 Yes 9 (12.9) Yes 22 (31.4)
Dental manipulations Dyslipidemia
 No 30 (42.9) No 60 (85.7)
 Yes 40 (57.1) Yes 10 (14.3)
Blood transfusion Hepatomegaly
 No 59 (84.3) No 36 (51.4)
 Yes 11 (15.7) Yes 34 (48.6)
Metabolic syndrome
 No 45 (64.3)   
 Yes 25 (35.7)